FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells

International Journal of Cancer

Volumn 118, Issue 7, 2006, Pages 1692-1698

  Kim, Cheol Hyeon ^a,b   Yoo, Jung Sun ^a,b   Lee, Choon Taek ^c,d   Kim, Young Whan ^c,d   Han, Sung Koo ^c,d   Shim, Young Soo ^c,d   Yoo, Chul Gyu ^c,d  

^a Korea Cancer Center Hospital   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

Apoptosis; Bcl 2 protein; Fragile histidine triad (FHIT); Lung neoplasms; Paclitaxel

Indexed keywords

CASPASE 7; CASPASE 8; FRAGILE HISTIDINE TRIAD PROTEIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EVALUATION; GENE DELETION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ACID ANHYDRIDE HYDROLASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 7; CASPASE 8; CASPASES; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PACLITAXEL; PLASMIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33644855857     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21573     Document Type: Article

References (39)

1. Brauch H, Johnson B, Hovis J, Yano T, Gazdar A, Pettengill OS, Graziano S, Sorenson GD, Poiesz BJ, Minna J, Linehan M, Zbar B. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med 1987;317: 1109-13.
2. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 1987;329:451-4.
3. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chromosome 3, 13, 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 1987;84:9252-6.
4. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 1992;7:445-9.
5. Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:1989-97.
6. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J Am Med Assoc 1995; 273:558-63.
7. Killary AM, Wolf ME, Giambernardi TA, Naylor SL. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 1992;89:10877-81.
8. Daly MC, Xiang RH, Buchhagen D, Hensel CH, Garcia DK, Killary AM, Minna JD, Naylor SL. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 1993;8:1721-9.
9. Kok K, Hofstra R, Pilz A, van den Berg A, Terpstra P, Buys CH, Carritt B. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin activation enzyme. Proc Natl Acad Sci USA 1993;90:6071-5.
10. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI, Minna JD. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 1994;9:1599-604.
11. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3pl4.2 fragile site and renal carcinoma-associated t(3:8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
12. 4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with histidine triad (HIT) family. Biochem J 1995;312:925-32.
13. 3-triphosphate hydrolase. Biochemistry 1996;35:11529-35.
14. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J, Huebner K. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996;56:978-83.
15. Sozzi G, Alder H, Tornielli S, Corletto V, Baffa R, Veronese ML, Negrini M, Pilotti S, Pierotti MA, Huebner K, Croce CM. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res 1996;56:2472-4.
16. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9.
17. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-5.
18. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
19. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T, Takahashi T. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-82.
20. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-67.
21. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-12.
22. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999;96:8489-92.
23. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-9.
24. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-20.
25. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
26. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
27. Roth JA, Grammer SF. Tumor suppressor gene therapy. Methods Mol Biol 2003;223:577-98.
28. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, Croce CM. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84.
29. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36.
30. Sevignani C, Calin GA, Cesari R, Sard M, Ishii H, Yendamuri S, Vecchione A, Trapasso F, Croce CM. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003;63:1183-7.
31. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771-6.
32. Ottey M, Han SY, Druck T, Barnoski BL, McCorkell KA, Croce CM, Raventos-Suarez C, Fairchild CR, Wang Y, Huebner K. FMi-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004;91:1669-77.
33. Hu B, Han SY, Wang X, Ottey M, Potoczek MB, Dicker A, Huebner K, Wang Y. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 2005;202:518-23.
34. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61.
35. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
36. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-50.
37. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86.
38. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003;15:691-9.
39. Askari MD, Vo-Dinh T. Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. Biopolymers 2004;73:510-23.